Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents
← catalyst calendarNCT07660198 · readout in 470 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Prevention
Enrollment
1,200estimated
Sites
44
Countries
Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-15 | actual | When the study began enrolling |
| Primary completion | 2027-12-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-02 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pneumococcal Disease
Interventions
- Biological: PG4
- Biological: 20-valent pneumococcal conjugate vaccine (20vPnC) — also filed as Prevnar 20
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants With Local Reactions Within 7 Days After Vaccination
measured Within 7 days after Vaccination
Percentage of Participants With Systemic Events Within 7 Days after Vaccination
measured Within 7 days after Vaccination
Percentage of Participants With Adverse Events (AEs)
measured From Vaccination to 1 month after Vaccination
Percentage of Participants With Serious Adverse Events (SAEs)
measured From Vaccination to 6 months after Vaccination
GMCs of serotype-specific IgG concentrations
measured 1 month after vaccination
GMTs of serotype-specific OPA titers
measured 1 month after vaccination
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed